SPDR S&P Biotech ETF
706 hedge funds and large institutions have $7.15B invested in SPDR S&P Biotech ETF in 2023 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 183 increasing their positions, 271 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
706
Holders Change
-2
Holders Change %
-0.28%
% of All Funds
11.13%
Holding in Top 10
19
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-17.39%
% of All Funds
0.3%
New
70
Increased
183
Reduced
271
Closed
67
Calls
$1.15B
Puts
$1.8B
Net Calls
-$653M
Net Calls Change
-$109M
Top Buyers
| 1 |
Goldman Sachs
New York
|
$858M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
$226M |
| 3 |
SG Americas Securities
New York
|
$55.5M |
| 4 |
Jane Street
New York
|
$156M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
$26M |
Top Sellers
| 1 |
Barclays
London,
United Kingdom
|
$104M |
| 2 |
JPMorgan Chase & Co
New York
|
$423M |
| 3 |
Two Sigma Advisers
New York
|
$2.53M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
$891M |
| 5 |
Citigroup
New York
|
$404M |
